Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Pulmonary Disease, Chronic Obstructive 1Pneumonia 1Colonic Neoplasms 1

Interventions

Cisplatin 168Radiotherapy 110pembrolizumab 96Cetuximab 95Docetaxel 74Carboplatin 74Radiotherapy, Intensity-Modulated 55Paclitaxel 51Nivolumab 50Fluorouracil 47Surgical Procedures, Operative 28Radiation 26Magnetic Resonance Spectroscopy 25durvalumab 23Drug Therapy 23Radiosurgery 21Biopsy 19Albumin-Bound Paclitaxel 19130-nm albumin-bound paclitaxel 18Taxes 17tislelizumab 16toripalimab 15Chemoradiotherapy 15Neoadjuvant Therapy 14Erlotinib Hydrochloride 14Blood Specimen Collection 14camrelizumab 13Immunohistochemistry 13Specimen Handling 12tremelimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Squamous Cell Carcinoma of Head and Neck × CIMAvax EGF × Clear all
NCT02955290 2025-11-10

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
51 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡